AI assistant
Neuland Laboratories Limited. — Call Transcript 2025
Feb 3, 2025
62255_rns_2025-02-03_feb6ce5b-57ad-4079-9a8a-4c32056eeb21.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [595 x 124] intentionally omitted <==
February 3, 2025
To BSE Limited Phiroze Jeejeebhoy Towers, 25[th] Floor, Dalal Street, Mumbai – 400 001
Scrip Code: 524558
The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai – 400 001
Scrip Code: NEULANDLAB; Series: EQ
Dear Sir/Madam,
Sub: Earnings Call Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the schedule of Q3 FY 2025 Earnings Call details.
This is for your information and records.
Yours sincerely,
For Neuland Laboratories Limited
Digitally signed by SARADA SARADA BHAMIDIPATI BHAMIDIPATI Date: 2025.02.03 12:14:50 +05'30' Sarada Bhamidipati Company Secretary
Encl: As above
==> picture [596 x 45] intentionally omitted <==
==> picture [143 x 37] intentionally omitted <==
Neuland Laboratories Limited’s Q3FY25 Results Conference Call
Neuland Laboratories Limited will announce its results for the third quarter and nine months ended December 31, 2024 on February 10, 2025. The results will also be made available on the website of the Company, www.neulandlabs.com
Following the announcement, the management of the Company will host an Earnings Call on February 11, 2025 at 16:00 hrs.
The details of the earnings call are:
Date: Time: February 11, 2025 16:00 Hrs (IST)
For Diamond Pass Registration Please Click Here:
Diamond Pass
About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)
For over 4 decades, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 100 APIs and has filed around 978+ Regulatory filings in the US (70 active US DMFs), the European Union (EU) and other geographies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI “SID & GP” Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.
For more information, visit www.NeulandLabs.com
For more queries please contact:
Neuland: [email protected] Ravi Udeshi: [email protected]